Navigation Links
VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
Date:12/4/2008

First Selective TLR8 Agonist to Advance to Clinical Trials

SAN DIEGO, Dec. 4 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 (TLR8) agonists for the treatment of cancer, respiratory and autoimmune diseases, announced today that it has initiated a Phase I clinical trial of VTX-2337, a selective TLR8 agonist for the treatment of cancer. The multi-center clinical trial is being conducted at the Mayo Clinic Arizona and TGen Drug Development Services (TD2) both in Scottsdale, Arizona.

"We are delighted to advance the first molecule from our Toll-Like Receptor 8 platform, VTX-2337, into the clinic," said Michael Kamdar, Executive Vice President and Chief Business Officer at VentiRx. "This represents a significant milestone for VentiRx and our TLR efforts as we have rapidly advanced into a clinical development company with a novel molecule that may have broad application in the treatment of cancer."

VTX-2337 is a small molecule TLR8 agonist that is expected to be used in combination with standard of care for the treatment of patients with cancer. Preclinical evaluation of VTX-2337 suggests that it may play a key role in augmenting the innate arm of the immune system and provide a valuable addition to various treatment regimens in oncology. The first clinical trial will investigate the safety and pharmacology of multiple doses of VTX-2337 in patients with late stage cancer.

"VTX-2337 is the first selective TLR8 compound to reach the clinic and we are hopeful that modulation of the innate immune response will provide a benefit to patients in a number of oncology indications," said Dr. Robert Hershberg, Executive Vice President and Chief Medical Officer at VentiRx.

About VentiRx Pharmaceuticals

VentiRx Pharmaceuticals, Inc. is a biopharmaceutical company committed t
'/>"/>

SOURCE VentiRx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... China , Jan. 23, 2015 Tianyin Pharmaceutical ... company that specializes in the development and sale of ... generics and active pharmaceutical ingredients (API) today announced the ... (JCM) API operation. 1. Following the September ...
(Date:1/22/2015)... RMD ) today announced results for its quarter ... million, a 10 percent increase compared to the quarter ended ... currency basis). Net income was $91.2 million, an increase of ... Diluted earnings per share for the quarter were $0.64, an ...
(Date:1/22/2015)... , Jan. 22, 2015  Profil Institute for Clinical Research, ... and obesity, announced today a new textbook,  Translational Research ... by Springer, a leading global scientific publisher. ... illustrate techniques for use in early phase clinical studies ...
Breaking Medicine Technology:TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3
... BRISBANE, Australia, Feb. 13 Progen,Pharmaceuticals Limited ... efficacy results from a phase 2 investigator-initiated ... agent Taxotere(R),(docetaxel) administered to patients with prostate ... Sydney Haematology and Oncology Clinics, the,principal investigator ...
... demonstrates,for the first time that embryonic stem cells can ... finding which is an important step,in the utilization of ... bone marrow transplantation. This hopeful news for patients with,severe ... was prepublished online in Blood, the official journal of ...
Cached Medicine Technology:Preliminary PI-88 Phase 2 Prostate Cancer Results to be Presented at the American Society for Clinical Oncology (ASCO) 2008 Genitourinary Cancer Symposium 2Preliminary PI-88 Phase 2 Prostate Cancer Results to be Presented at the American Society for Clinical Oncology (ASCO) 2008 Genitourinary Cancer Symposium 3A Functional Immune System Can Be Derived From Embryonic Stem Cells, Preliminary Study Finds 2A Functional Immune System Can Be Derived From Embryonic Stem Cells, Preliminary Study Finds 3
(Date:1/22/2015)... Calif. (PRWEB) January 22, 2015 ... Susan Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were ... their leadership in advancing biotechnology, biomedical science, medical ... and Olsen each received the “2014 Life Sciences ...
(Date:1/22/2015)... January 22, 2015 IsoComforter, Inc. has introduced ... with patented IsoTube design to treat specific body parts and ... most progressive and easy to use patented cold therapy machine ... sports related orthopedic and muscle injuries. IsoComforter has become ...
(Date:1/22/2015)... 2015 Payday lending practices in four ... cause financial distress to the states that permit them, ... University’s Center on Race and Wealth. , While they ... payday loans at the same time substantially depress economic ...
(Date:1/22/2015)... As interest in the value of spiritual ... worldwide, Rev. Eric J. Hall , president and CEO ... will be the keynote speaker on January 27 at an ... system. , The conference, “Hope and Resilience: Innovative and Interdisciplinary ...
(Date:1/22/2015)... a new blog post presenting a list of vehicles that cannot ... Some types of vehicles cannot be covered under an ordinary auto ... see if their vehicle qualifies for auto insurance coverage. , ... that cannot be covered by a plan. Clients have little options ...
Breaking Medicine News(10 mins):Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2
... HealthDay Reporter , MONDAY, April 25 (HealthDay News) -- ... it does not adequately protect children and pregnant women, ... position paper from the American Academy of Pediatrics claims. ... (TSCA) in 1976, tens of thousands of new chemicals ...
... Association of Anatomist,s (AAA) presented its highest awards on ... DC. This year,s honors went to: Bjorn ... Harvard Medical School, Professor of Developmental Biology and Dean ... Olsen received the 2011 Henry Gray/ Lippincott Williams & ...
... Pelvic organs given the slip by the protein fibulin-5 ... condition that affects almost 50% of women over the ... ligaments supporting a woman,s pelvic organs weaken such that ... into the vagina. For many affected women, treatment involves ...
... -- Some college students felt real distress when their favorite ... of 2007-2008, a new report suggests. Most affected were ... opposed to simply for passing the time -- and who ... authors noted. "We found that people who primarily watched ...
... class of drugs that shows promise in breast and ovarian ... patients with a different genetic mutation, a new study from ... in cell lines from colorectal cancer patients, researchers found that ... tumors with mutations in the MRE11 gene. About ...
... Cancer has a mighty big bag of tricks that it ... Among those tricks is one that allows tumor cells to ... something of a highway to metastasis. Yet research unveiled this ... put the brakes on such cancer spread, and the researchers ...
Cached Medicine News:Health News:Pediatricians Urge Better Protection From Chemicals 2Health News:Pediatricians Urge Better Protection From Chemicals 3Health News:JCI table of contents: April 25, 2011 2Health News:JCI table of contents: April 25, 2011 3Health News:JCI table of contents: April 25, 2011 4Health News:JCI table of contents: April 25, 2011 5Health News:JCI table of contents: April 25, 2011 6Health News:Some TV Fans 'Distressed' Without Favorite Shows: Study 2Health News:New class of cancer drugs could work in colon cancers with genetic mutation, U-M study finds 2Health News:Laying bare the not-so-sweet tale of a sugar and its role in the spread of cancer 2Health News:Laying bare the not-so-sweet tale of a sugar and its role in the spread of cancer 3
Binocular indirect ophthalmic lenses. Small pupil diagnosis & treatment....
Binocular indirect ophthalmic lenses. General diagnosis & treatment....
Binocular indirect ophthalmic lenses. Ultra magnification of posterior pole....
... Volk's super ... biomicroscopy lenses. Examination ... Provide unprecedented fundus ... addressing maximum potential ...
Medicine Products: